Core Viewpoint - Hanyu Pharmaceutical has signed strategic investment and cooperation agreements with Shenzhen Carbon Cloud Peptide Pharmaceutical Technology Co., Ltd to enhance collaboration in peptide drug development and industrialization [1][2] Group 1: Agreements and Collaborations - The agreements include a strategic investment in Carbon Cloud Peptide and a strategic cooperation for CRDMO services in innovative drugs [1] - Previous collaboration began with a framework agreement in 2024, focusing on leveraging Hanyu's capabilities in peptide drug industrialization and Carbon Cloud's advanced technology in peptide screening using AI [1][2] - A joint development agreement for a GLP-1R/GIPR/GCGR triple agonist innovative drug project was established in May 2025, laying a solid foundation for further cooperation [1] Group 2: Project Development and Support - Hanyu Pharmaceutical will utilize its CRDMO technical platform and industrialization advantages to support multiple innovative drug projects under Carbon Cloud, including PDC peptide conjugated drugs and AI antibacterial peptides [2] - The cooperation encompasses the entire process from preclinical research to commercialization, covering key aspects such as active pharmaceutical ingredient process optimization, formulation development, quality research, registration, and large-scale production [2] - Industry analysts believe this collaboration will strengthen Hanyu's industrial synergy in the peptide CRDMO service chain and accelerate the commercialization of innovative products for Carbon Cloud, achieving resource sharing and complementary advantages [2]